News

Latest news and events from Oxford MEStar

Oxford MEStar to collaborate with Cell and Gene Therapy Catapult and AK (Suzhou) Biomedical as part of Jiangsu-UK industrial challenge programme

Grant to support development of novel manufacturing system to assist in production of innovative cancer treatments Oxford, UK, 05 December 2017 – Oxford MEStar, in collaboration with the Cell and Gene Therapy (CGT) Catapult and AK (Suzhou) Biomedical, today announced it has been awarded a share of a £1 million grant from the Innovate UK-Jiangsu […]


Oxford MESTAR, collaborated with UCL and China partners, awarded Innovate UK-MoST grant to develop novel treatment for osteoarthritis

Oxford MESTAR Ltd, in collaboration with an interdisciplinary UCL team from Division of Surgery & Interventional Science and partners in China (Tsinghua University and Shenzhen Lando Co. Ltd), has been awarded a £2m Innovate UK-MoST grant to develop novel osteochondral scaffold technology as a treatment for early intervention of osteoarthritis.   Osteochondral scaffold technology is […]


Oxford MEStar announces non-binding LOI with Elanix Biotechnologies

PRESS RELEASE Oxford MEStar announces non-binding letter of intent with Elanix Biotechnologies in regard to setting up a JV to market GynRepair in China Oxford, 22 November, 2016 Oxford MEStar Ltd (“MEStar”), an Oxford University spin-out, today announced that the company has entered into a non-binding letter of intent (LOI) with Elanix Biotechnologies AG.  The […]


Oxford MEStar to develop diagnostic products in cancer and infectious diseases using intellectual property acquired from University of Glasgow spin-out, Mode Diagnostics Limited.

Oxford MEStar Ltd (“MEStar”), an Oxford University spin-out, has acquired selected intellectual property, trademarks and assets from Mode Diagnostics Ltd (“Mode”) for an undisclosed sum. Professor Zhanfeng Cui, the founder of MEStar, commented: “We are excited about the long term commercial potential of using this technology. We believe the IP developed by Mode, a proprietary […]


Partnership with UCL and Collagen Solutions Plc in grant funded project

Oxford MEStar Ltd, a rapidly growing company specialising in translational and regenerative medicine, announces that it is part of a consortium that has been awarded an Arthritis Research UK (ARUK) Point of Care grant to develop novel functionally man-made osteochondral scaffold for large osteochondral defect repairs. Osteochondral injury refers to repetitive trauma within a joint […]